文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

突变p53再激活与DNA去甲基化联合治疗AML/MDS

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.
PubMed 文献 · Sci Transl Med · 2026-08-12

携带p53突变的急性髓系白血病/骨髓增生异常综合征(AML/MDS)对多种标准治疗无效。研究显示三氧化二砷(ATO)可恢复p53结构突变体功能,并通过直接反式激活IRF7增强地西他滨触发的干扰素反应。首次人体试验(PANDA-T0)中5例p53结构突变患者接受ATO联合地西他滨治疗,4例达骨髓完全缓解,不良事件可控。

要点

  • ATO联合地西他滨在p53结构突变AML/MDS中显示可控安全性和初步疗效。
  • ATO恢复的突变p53通过反式激活IRF7增强地西他滨诱导的干扰素反应。
  • 地西他滨通过p53-serine-20磷酸化和抑制MDM2增强ATO恢复的突变p53活性。

核心结论

  • ATO联合地西他滨为p53突变AML/MDS提供替代治疗方案,并建立区分p53突变类型的靶向治疗概念框架。

研究设计与样本

  • 临床前研究结合首次人体试点临床试验(PANDA-T0,NCT03855371),纳入5例携带p53结构突变的AML/MDS患者。
  • 另对瑞金AML/MDS样本库中103例p53突变患者样本进行分析,鉴定出48种不同的p53错义突变体。

主要发现

  • ATO和地西他滨联合在p53突变AML细胞系中诱导细胞死亡,并在细胞系来源异种移植模型中抑制肿瘤生长。
  • PANDA-T0试验中5例患者接受ATO联合地西他滨治疗,不良事件可控,4例达到骨髓水平完全缓解,伴随p53激活和干扰素反应。
  • 103例p53突变患者中鉴定出48种不同p53错义突变体,其中21种因共处理后可激活p53和干扰素反应而被归类为ATO联合地西他滨方案适用。

关键数值与推荐

  • PANDA-T0试验纳入5例携带p53结构突变的AML/MDS患者,4例达到骨髓完全缓解。
  • 103例p53突变患者中48种错义突变体,21种被分类为ATO联合地西他滨方案适用。

临床怎么用

  • 对于携带p53结构突变的AML/MDS患者,可考虑ATO联合地西他滨方案,但需根据p53突变类型评估适用性。

局限性

  • PANDA-T0为首次人体试点试验,样本量仅5例,需更大规模研究验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia/myelodysplastic syndromes (AML/MDSs) carrying p53 mutations are refractory to various standard therapies. Arsenic trioxide (ATO) may be effective in restoring function to p53 structural mutants. Here, we report that mutant p53 rescued by ATO treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine by transactivating interferon regulatory factor 7 (IRF7) directly. Decitabine also increased the transactivation activity of ATO-rescued mutant p53 by inducing p53-serine-20 phosphorylation and blocking p53-inhibitory mouse double minute 2 homolog (MDM2). ATO and decitabine together killed p53-mutant AML cells and suppressed tumor growth in cell line-derived xenografts. In a first-in-human pilot clinical trial for testing the combination of ATO and decitabine (PANDA-T0 trial, NCT03855371), which enrolled five patients with AML/MDS harboring p53 structural mutations, the ATO and decitabine regimen produced manageable adverse events, and four of the five treated patients achieved complete remission at the level of the bone marrow, associated with p53 activation and interferon response. In 103 p53-mutant patients whose samples were deposited in Ruijin AML/MDS sample repository, 48 distinct p53 missense mutants were identified, 21 of which were classified as ATO and decitabine regimen applicable because of their competencies in activating p53 and interferon responses upon cotreatment. This study establishes an alternative treatment regimen for patients with p53-mutant AML/MDS and provides a proof-of-concept framework for p53-targeted therapy that differentiates between p53 mutations.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Song H, Chen X, Xiao S, et al. Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS. Sci Transl Med. 2026. PMID: 42585289. doi:10.1126/scitranslmed.ads9325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。